Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.60 |
| ▸ | MAOA | P21397 | 3/20 | 0.60 |
| ▸ | RXRA | P19793 | 1/20 | 0.57 |
| ▸ | RXRB | P28702 | 1/20 | 0.57 |
| ▸ | RXRG | P48443 | 1/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425852 | 0.86 | MAOB (0.57) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL4425854 | 0.86 | MAOB (0.57) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL13946908 | 0.78 | MAOB (0.60) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL7398313 | 0.78 | MAOB (0.62) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL8935327 | 0.77 | MAOB (0.58) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL1070556 | 0.77 | MAOB (0.55) | MAOBMAOARXRARXRBRXRG | |
| Hydrochloric Acid SCHEMBL8935265 | 0.77 | MAOB (0.63) | MAOBMAOARXRARXRBRXRG | |
| SCHEMBL31060850 | 0.76 | MAOB (0.76) | MAOBMAOA | |
| SCHEMBL2018555 | 0.76 | MAOB (0.76) | MAOBMAOA | |
| SCHEMBL964395 | 0.76 | MAOB (0.76) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7253318-B2 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2007-08-07 | — | — | US | disclosed |
| EP-1761480-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000324-A2 | NEW MAO-B INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | HOFFMAN-LA ROCHE INC. | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288367-A1 | Benzyloxy derivatives as MAOB inhibitors | MAOB, MAOA, COMT | MAOB 1/4885MAOA 2/4885RXRA 3696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.